drugset / Trial / NCT00141713

The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease

NCT00141713

Phase 2 Completed 40 enrolled University of Michigan Rogel Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

Etanercept (Enbrel) will be added to standard therapy for acute Graft-versus-Host Disease to see if the effectiveness of standard therapy can be improved. Partial Funding Source- FDA OOPD

Timeline

Start
2003-10
Primary completion
2006-11
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 0.4 mg/kg Subcutaneous